CG Oncology (CGON) EBITDA Margin Growth (3y) (2026)

CG Oncology (CGON) EBITDA Margin Growth (3y) (2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - -
2 Nanobiotix 1,908.96 Bn 1,908.90 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 474.03 Bn 469.24 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.96 Bn 50.77 Bn 1.41 Bn -623.00
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn 6,993.00
10 CG Oncology 6.18 Bn 6.18 Bn -1.88 Mn -111,928.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -111,928.00